Reassurance over cancer risk in TNFi

RA patients treated with TNFi therapy had no overall increased risk of malignancy compared with the general population or with biologic-naïve patients, Australian researchers show.

The results are consistent with previously reported observational studies, the investigators led by Professor Rachelle Buchbinder from Monash University write in the journal BMC Musculoskeletal Disorders.

Nearly 3000